Myricetin Possesses Potential Protective Effects on Diabetic Cardiomyopathy through Inhibiting IκBα/NFκB and Enhancing Nrf2/HO-1

Table 3

Effects of myricetin on echocardiographic parameters. LVEDs: left ventricle-end-systolic diameter; LVEDd: LV-end-diastolic diameter; IVSd: end-diastolic interventricular septal thickness; IVSs: end-systolic interventricular thickness; LVPWd: end-diastolic LV posterior wall thickness; LVPWs: end-systolic LV posterior wall thickness; FS: fractional shortening; EF: LV ejection fraction. Data were presented as means ± SEM; compared with CON or M group; ^# compared with STZ group.

	CON	M	STZ	STZ + M
n	12	12	16	16
HR	530.81 ± 20.39	547.30 ± 22.88	514.91 ± 19.43	536.62 ± 29.74
LVEDd	3.79 ± 0.086	3.81 ± 0.089	3.65 ± 0.102^∗	3.71 ± 0.181^#
LVEDs	1.86 ± 0.070	1.89 ± 0.058	2.33 ± 0.081^∗	2.06 ± 0.104^#
IVSd	0.73 ± 0.046	0.73 ± 0.035	0.66 ± 0.037^∗	0.70 ± 0.043^#
IVSs	1.22 ± 0.098	1.20 ± 0.071	0.94 ± 0.010^∗	1.03 ± 0.067
LVPWd	0.71 ± 0.057	0.68 ± 0.138	0.67 ± 0.052	0.71 ± 0.043
LVPWs	1.29 ± 0.070	1.25 ± 0.085	1.09 ± 0.095^∗	1.18 ± 0.093^#
EF	82.11 ± 0.679	81.49 ± 0.877	66.72 ± 4.513^∗	76.54 ± 2.39^#
FS	49.93 ± 1.59	50.39 ± 1.14	36.13 ± 3.26^∗	44.37 ± 1.67^#